Fred W. Manak
Plus aucun poste en cours
Profil
Fred W.
Manak held former positions as Executive Director-Trade & Pricing at Amgen, Inc., Vice President-Reimbursement at Onyx Pharmaceuticals, Inc., Vice President-Market Access at InterMune, Inc., and Vice President-Access & Reimbursement at ACADIA Pharmaceuticals, Inc. He obtained an undergraduate degree from Muhlenberg College.
Anciens postes connus de Fred W. Manak
| Sociétés | Poste | Fin |
|---|---|---|
| INTERMUNE INC | Corporate Officer/Principal | - |
Onyx Pharmaceuticals, Inc.
 Onyx Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Onyx Pharmaceuticals, Inc. operates as a biopharmaceutical company. It engages in developing innovative therapies that target the molecular mechanisms that cause cancer. The company was founded by Frank McCormick in February 1992 and is headquartered in Thousand Oaks, CA. | Corporate Officer/Principal | - |
| AMGEN INC. | Corporate Officer/Principal | - |
| ACADIA PHARMACEUTICALS INC. | Corporate Officer/Principal | - |
Formation de Fred W. Manak
| Muhlenberg College | Undergraduate Degree |
Expériences
Fonctions occupées
Sociétés liées
| Sociétés cotées | 2 |
|---|---|
| ACADIA PHARMACEUTICALS INC. | Health Technology |
| AMGEN INC. | Health Technology |
| Entreprise privées | 2 |
|---|---|
Onyx Pharmaceuticals, Inc.
Onyx Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Onyx Pharmaceuticals, Inc. operates as a biopharmaceutical company. It engages in developing innovative therapies that target the molecular mechanisms that cause cancer. The company was founded by Frank McCormick in February 1992 and is headquartered in Thousand Oaks, CA. | Health Technology |
InterMune, Inc.
 InterMune, Inc. BiotechnologyHealth Technology InterMune, Inc. operates as a biotechnology company that researches, develops and commercializes therapies in pulmonology and orphan fibrotic diseases. It focuses on therapies for the treatment of idiopathic pulmonary fibrosis, a progressive and fatal lung disease. The firms research programs are focused on the discovery of targeted, small-molecule therapeutics and biomarkers to treat and monitor serious pulmonary and fibrotic diseases. The company was founded in 1998 and is headquartered in South San Francisco, CA. | Health Technology |